Britain’s competition regulator has been told to review its evidence against US drugmaker Pfizer and Flynn Pharma in the UK as it seeks to reinstate a record £90m fine for excessive drug pricing, reported The Financial Times.
Featured News
Paul Weiss Bolsters M&A Practice With Senior Partner Hire From Goodwin
Nov 16, 2026 by
CPI
Samsung, SK Hynix and Micron Lose Bid to Dismiss US DRAM Antitrust Suit
Nov 16, 2026 by
CPI
US Attorney Warns Warren Over Plans to Scrutinize Trump-Linked Deals
Nov 16, 2026 by
CPI
EU Clears UniCredit’s Commerzbank Acquisition Without Conditions
Nov 16, 2026 by
CPI
Europe’s Smaller Soccer Clubs Take on UEFA in Antitrust Fight
Nov 16, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner